Boston Biomedical is a private biotech company founded in November, 2006 by Chiang J. Li, MD FACP to provide employment for R&D scientists facing imminent layoff. This team of would-be layoff scientists has overcome exceptional financial hardship and developed, from scratch, a world-leading clinical-stage product pipeline targeting cancer stem cells.

Cancer stem cells (CSCs) are considered to be fundamentally responsible for malignant growth, metastasis, and cancer treatment failure. Targeting CSCs is an emerging approach for the development of the next generation of oncology therapeutics. Boston Biomedical has developed a leading pipeline of cancer cell stemness inhibitors that includes BBI608, BBI503, as well as a highly productive drug-discovery engine.

BBI608 is a first-in-class, orally-administered, cancer stem cell inhibitor currently in preparation for Phase III trials in patients with colorectal cancer in North America, as well as various Phase Ib trials and Phase II trials for multiple solid tumors. BBI608, through its undisclosed molecular target, simultaneously inhibits multiple key cancer stemness pathways. BBI608 targets highly malignant CSCs as well as heterogeneous cancer cells. In clinical trials to date, BBI608 has shown excellent safety, favorable pharmacokinetics, and encouraging signs of anti-cancer activity against a broad range of tumor types.

BBI503 is a first-in-class, orally-administered, cancer stemness kinase inhibitor currently in multi-center Phase I trials in patients with various solid tumors in North America. BBI503, through its undisclosed molecular target, kills highly malignant CSCs, as well as heterogeneous cancer cells. BBI503 was selected as the recipient of a US NCI cancer stem cell initiative grant award in 2010.

Boston Biomedical is financially supported by Mitsui & Co. Global Investment, Alexandria Real Estate Equities, Inc. [NYSE: ARE], and the National Institute of Health. With a board consisting of industry luminaries and prominent leaders including Dr. Bill Rutter, Mr. Joel Marcus and Mr. Taro Inaba, a seasoned management, and a highly innovative R&D staff, Boston Biomedical is well positioned to translate the exciting potential of its technologies to clinical benefits for patients with cancer. Boston Biomedical's innovation in drug discovery has received a number of recognitions and awards in the United States, including sole recipient of the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, and 2011 Biotech Pioneer (Alexandria Oncology Summit).